<?xml version="1.0" encoding="UTF-8"?>
<p id="p0170">Sofosbuvir was also recently shown to protect against Zika flavivirus (ZIKV) in studies both 
 <italic>in vitro</italic> and 
 <italic>in vivo</italic> (
 <xref rid="bib65" ref-type="bibr">Mesci et al., 2018</xref>; 
 <xref rid="bib12" ref-type="bibr">Bullard-Feibelman et al., 2017</xref>). It has been found that HCV and ZIKV RNA polymerases have very similar active sites, confirming that sofosbuvir could also act on ZIKV-infected cells. It was also demonstrated 
 <italic>via</italic> cellular assays and animal models that sofosbuvir inhibits the replication of other flaviviruses, such as dengue virus (DENV) (
 <xref rid="bib108" ref-type="bibr">Xu et al., 2017</xref>), yellow fever virus (YFV) (
 <xref rid="bib29" ref-type="bibr">De Freitas et al., 2019</xref>), and chikungunya virus (CHIKV) (
 <xref rid="bib35" ref-type="bibr">Ferreira et al., 2019</xref>).
</p>
